-
Adial Pharma-Backed Purnovate Selects PNV-5030 As Pain Management Candidate
Thursday, October 21, 2021 - 1:06pm | 279Read More...Adial Pharmaceuticals Inc (NASDAQ: ADIL) has announced data in a preclinical model of pain reduction. Based on the data, Adial's subsidiary Purnovate Inc selected PNV-5030 as the lead compound for its program to develop pain management drugs. PNV-5030 has been tested...
-
Atreca Inks Licensing Pact With Gates Research On Malaria Antibody
Thursday, October 21, 2021 - 8:58am | 210Read More...Atreca Inc (NASDAQ: BCEL) has entered into a licensing agreement with the Bill & Melinda Gates Medical Research Institute to develop MAM01/ATRC-501 to prevent malaria. MAM01/ATRC-501 is a monoclonal antibody entering preclinical development. Under the agreement, Gates MRI...
-
Voyager Posts Encouraging Preclinical Data For CNS-Directed Gene Therapy
Wednesday, October 20, 2021 - 9:27am | 168Read More...Voyager Therapeutics Inc (NASDAQ: VYGR) has announced the presentation of preclinical data of GBA1 gene replacement therapy. The data demonstrated that a single intravenous (IV) dose of GBA1 gene replacement therapy achieved widespread distribution in the central nervous system (CNS...
-
Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology
Tuesday, October 19, 2021 - 3:55pm | 353Read More...Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs. The license does not include any rights to base...
-
Adagio Stock Jumps On Additional Preclinical Data For Its COVID-19 Antibody
Tuesday, October 19, 2021 - 8:31am | 258Read More...Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new in vitro data demonstrating retained neutralizing activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the newly emerged Lambda and Mu variants. Related: Adagio's COVID-19 Candidate...
-
Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs
Tuesday, October 19, 2021 - 6:54am | 338Read More...Wave Life Sciences Ltd (NASDAQ: WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK) to discontinue discovery & research of preclinical programs for central nervous system (CNS) indications over a four-year research term....
-
Mersana Highlights New Preclinical Data For XMT-2056 Cancer Settings
Friday, October 8, 2021 - 12:52pm | 274Read More...Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual International Conference. XMT-2056 is an Immunosynthen STING-agonist ADC candidate, targeting an epitope of human epidermal growth factor...
-
Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19
Friday, October 8, 2021 - 8:10am | 272Read More...Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studies were conducted independently by the Hadassah Medical Center, Israel. IMM124E is used to manufacture Immuron's flagship...
-
eFFECTOR Therapeutics Stock Gains On Encouraging Preclinical Zotatifin Data In Breast Cancer
Friday, October 8, 2021 - 7:34am | 297Read More...eFFECTOR Therapeutics Inc (NASDAQ: EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zotatifin in animal models of triple-negative breast cancer (TNBC). The data were at the 2021 AACR-NCI-EORTC International Conference...
-
Why Are Merus Shares Soaring Thursday?
Thursday, October 7, 2021 - 10:47am | 267Read More...Merus N.V. (NASDAQ: MRUS) has presented data on MCLA-158 and preclinical data on zenocutuzumab (Zeno) at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. Data from Phase 1 trial of MCLA-158 (petosemtamab) in advanced head and...
-
Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical Action
Wednesday, October 6, 2021 - 7:17am | 269Read More...Surrozen Inc (NASDAQ: SRZN) announced that preclinical data from its inflammatory bowel disease (IBD) program, SZN-1326, were presented during the 2021 United European Gastroenterology Week. Related: See Why Surrozen Stock Is Surging On Tuesday. Preclinical data of SZN-1326...
-
Inhibikase Shares Interim 3-Month Toxicology Studies Data Of Parkinson's Candidate
Monday, October 4, 2021 - 9:57am | 326Read More...Inhibikase Therapeutics Inc (NASDAQ: IKT) has announced interim three-month results from its ongoing chronic toxicology studies of oral IkT-148009 administered in rats and non-human primates (NHPs). The toxicology studies of IkT-148009 include daily oral administration in rats for...
-
Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program
Friday, October 1, 2021 - 10:21am | 290Read More...Dyne Therapeutics Inc (NASDAQ: DYN) has announced new data presented today during the 2021 Muscle Study Group Annual Scientific Meeting for its Duchenne muscular dystrophy (DMD) program. DMD is a rare disease caused by mutations in the gene that encodes for dystrophin, a protein...
-
See Why Alzamend Neuro Stock Is Rallying On Thursday
Thursday, September 30, 2021 - 1:45pm | 248Read More...Alzamend Neuro Inc (NASDAQ: ALZN) has received a written response to its meeting request regarding the FDA's Type B Pre‑Investigational New Drug (Pre-IND) application. Today's response provides a path for its planned clinical development of AL002, the Company says. AL002...
-
Merck, Sutro Biopharma Extends Cytokine Derivative Research Program
Thursday, September 30, 2021 - 9:18am | 308Read More...Merck & Co Inc (NYSE: MRK) has extended the research term by two years for the first cytokine derivative program under a 2018 agreement with Sutro Biopharma Inc (NASDAQ: STRO). The research extension is intended to facilitate preclinical research and development...
















